Anticoagulation and restenosis after percutaneous transluminal coronary angioplasty.
Restenosis after angioplasty is probably related to 2 processes: thrombosis and recurrence of atherosclerosis. Many approaches to altering these processes are available, but to date none has shown a high rate of success. Heparin has properties relevant to both processes; this makes it an attractive compound for further study. The anticoagulant action of heparin is well known. It is mediated primarily though complex formation with antithrombin III, which leads to a conformational change and an increased rate of thrombin inactivation. Heparin has additional antithrombotic actions, largely mediated through the formation of the same complex, but involving precursor elements such as factor Xa. These actions of heparin can be localized to different portions of the large, complex molecule. Additionally, experimental studies have demonstrated an antiproliferative action of heparin, a property that may be relevant to smooth muscle cell proliferation after angioplasty. This is mediated by a fairly small, functionally distinct nonanticoagulant portion of the heparin molecule. Fragments of heparin possessing particular actions are being investigated experimentally and clinically. Continued investigations of the structure and function of heparin promise to lead to a decreased rate of restenosis and a better understanding of the mechanisms of angioplasty.
D000800:Angioplasty, Balloon; D003327:Coronary Disease / Q000517:prevention & control / Q000628:therapy*; D003328:Coronary Thrombosis / Q000517:prevention & control; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D012008:Recurrence
D006493:Heparin